


SALES TRACTION POSITIVE, BUT REVENUE TIMING KEY FOR FY18 FINANCIALS

- XTEK Limited (XTE) is an Australian homeland security and defence specialist which has secured a substantial contract with the Australian Defence Force (ADF) for the sale of Small Unmanned Aerial Systems (SUAS) which forms a solid backbone for revenue growth. XTE also has substantial upside in sales of its in-house product suite, with the proprietary XTclave™ recently gaining traction with sales in Australia and Europe and with sales expected from XTAtlas™ in FY19. We maintain our Spec Buy rating and target price of \$1.14/sh.**
- FY18 Forecasts:** Revenue for the first nine months of FY18 was reported at \$8.3m and thus we expect XTE to reach well above the lower band of its stated revenue guidance of \$11-18m and to report gross profits in line with the historical margins of 20-40%. Using our base assumptions, we have forecast FY18 revenue of \$15.5m, gross profit of \$4.7m and EBITDA of \$0.3m.
- Revenue timing key to positive financials:** We note that timing and recognition of revenue could have a material impact on top line performance reported in FY18, with a large portion of sales and deliveries occurring close to the financial year end. If sales were to be pushed into FY19, it would mean that FY18 results would be on the lower end of guidance (and may be viewed negatively by the market) but would increase the revenue range in FY19.
- Scenario Analysis:** We have created base, bull and bear case scenarios based on the financial forecasts given by XTE in its Investor presentations. We note that all scenarios derive a valuation above the current share price and are not yet inclusive of the large potential revenue upside from the XTclave™ and XTAtlas™ product suites. Thus, XTE currently appears attractively priced. Our base case scenario derives a valuation of \$1.14/sh.
- XTclave™ Ramping up:** In early June 2018, XTE announced the first domestic order from the ADF for its Small Arms Protective Inserts (which are produced using the XTclave™ process) which is expected to be delivered by December 2018 and marks a significant milestone for the Company's proprietary product suite. XTE now has initial sales in Europe and Australia, and we expect it to ramp-up sales in FY19.
- Balance Sheet:** As at 31 March 2018, XTE had cash of \$3.6m and no debt. We expect the 2HFY18 to be stronger than the first, given the historical half year split seen in XTE's reporting. While XTE appears to not need a capital raising in the near-term, we believe the Company could return to market to shore up its balance sheet in the next 12 to 18 months; particularly if revenue trends more toward the bear case scenario

Year End June 30	2016A	2017A	2018F	2019F	2020F
Reported NPAT (\$m)	(1.6)	0.1	0.2	1.2	6.4
Recurrent NPAT (\$m)	(1.6)	0.1	0.2	1.2	6.4
Recurrent EPS (cents)	(6.2)	0.2	0.4	3.1	16.0
EPS Growth (%)	na	na	129.4	691.0	413.7
PER (x)	(7.4)	265.3	115.7	14.6	2.8
PEG	na	na	0.9	0.0	0.0
EBITDA (\$m)	(1.5)	0.2	0.3	1.7	6.8
EV/EBITDA (x)	(7.5)	69.0	49.7	9.1	1.9
Free Cashflow	(2.0)	(1.5)	(1.7)	0.0	2.6
FCFPS (cents)	(7.7)	(4.3)	(4.2)	0.0	6.4
PFCF (x)	(5.9)	(10.6)	(10.7)	18,088.7	7.1
DPS (cents)	0.0	0.0	0.0	0.0	0.0
Yield (%)	0.0	0.0	0.0	0.0	0.0
Franking (%)	0.0	0.0	0.0	0.0	0.0

4 July 2018		
12mth Rating		Spec Buy
Price	A\$	0.46
Target Price	A\$	1.14
12mth Total Return	%	151.5
RIC: XTE.AX		BBG: XTE AU
Shares o/s	m	39.9
Free Float	%	100.0
Market Cap.	A\$m	18.2
Net Debt (Cash)	A\$m	-4.1
Net Debt/Equity	%	na
3mth Av. D. T'over	A\$m	0.014
52wk High/Low	A\$	0.68/0.43
2yr adj. beta		0.90
Valuation:		
Methodology		DCF
Value per share	A\$	1.14
Analyst: Jon Scholtz		
Phone: (+61) 8 9225 2836		
Email: jscholtz@psl.com.au		

12 Month Share Price Performance



Performance %	1mth	3mth	12mth
Absolute	(15.7)	(22.9)	(8.1)
Rel. S&P/ASX 300	(18.8)	(30.2)	(15.5)

PRODUCTS AND TIMELINE

XTE has three distinct business verticals, with numerous products and services in each. XTE is an accredited value added reseller of leading global defence products (such as SUAS). It provides services, training, support and consultancy to the Australian homeland security and defence market and develops and manufactures a range of in-house products which are to be commercialised domestically and, via resellers, into the international defence market.

XTE has three key sales and marketing strategies including: exclusive distribution agreements with leading global security brands; aftersales services, training, support and consultancy, and developing and commercialising a range of new technologies for the domestic and international defence markets.

Unmanned Aerial Systems (UAS)

In July 2017, XTE signed the contract for the supply of Small Unmanned Aerial Systems (SUAS) capability for the Australian Defence Force (ADF) as part of the Federal Government's planned \$101m investment in this capability. The SUAS contract represents a major step-change for XTEK in terms of sales. The Group could generate revenue of approximately \$40m from the acquisition of the systems over the next three years and up to \$9m per annum through the provision of maintenance and support activities over the next five to seven years for sustainment of the SUAS capability. This is in addition to the supply of SUAS, spare parts and maintenance worth \$10m over the past three years.

Revenue from this commercial agreement with the ADF forms the basis of our financial forecasts, with the range (as set out by the Company) shown in Figure 1 below. Revenue for the first nine months of FY18 was reported at \$8.3m and thus we expect XTE to reach well above the lower band of its stated guidance (\$11-\$18m). However, timing and revenue recognition could significantly impact the quantum of revenue reported for the full year as a majority of orders are placed and delivered at close to financial year end.

XTatlas™

Geospatial video overlays and mosaic mapping from video in near-real time

XTatlas™ is a ground-breaking new Small Unmanned Aircraft System (SUAS), developed by XTEK. This new SUAS application allows real time, accurate geo-referenced video mapping. Traditionally, mapping accurate georeferenced capabilities could not be conducted in real-time, and it can take several hours to compute data from a mission to match up to map references. XTatlas™ offers a real-time capability that allows the user to view georeferenced video providing the operator instant situational awareness during a mission. The live video and geolocated maps can be transmitted over a network for viewing at a remote command post. As a major benefit, XTatlas™ should provide digital targeting to the local operator of a SUAS.

During the past year, XTE continued development of the XTatlas™ digital imagery technology. Commercialisation pathways for XTatlas™ has commenced, with global demand being identified from UAV operators, defence and homeland security agencies. This has stimulated interest from a range of potential clients. XTatlas™ sales are expected in FY19.

XTclave™

Composite consolidation technology production plant

XTclave™ makes it possible to manufacture lighter, stronger and stiffer composite articles more efficiently, such as small arms protective insert (SAPI) plates that may be up to 30% lighter.

Significant XTclave™ development and testing work on advanced lightweight hard armour body plate solutions for defence applications was undertaken during the past year, mainly with the US Department of Defence (DOD). XTE reported that further independent testing has confirmed that up to 30% weight reduction has been achieved for polyethylene plates, whilst still providing a similar level of ballistic protection delivered by plates manufactured by traditional means. XTE is finalising the build of a new commercial scale XTclave™ plant and product development opportunities will continue to be investigated across the Global Composites Market. In early June 2018, XTE announced the first domestic order from the ADF for its Small Arms Protective Inserts (which are produced using the XTclave™ process) which is expected to be delivered by December 2018 and marks a significant milestone for the Company's proprietary product suite.

XTE now has initial sales in Europe and Australia, and we expect it to ramp-up sales in FY19.

FINANCIALS


FY17 was a profitable period for XTE. It generated \$9.0m in revenue and reported a net profit after tax (NPAT) of \$0.1m. XTE has also given revenue guidance for FY18 of A\$11-18m, and expects gross profits to be in line with the historical revenue margins of 20-40%. We note that in FY17 the gross profit margin was 38%, and we have forecast 30% for FY18 onward.

XTE has stated that it should continue to be cash flow positive going forward, and while the half year results were relatively soft, 2HFY18 results should be stronger (which is in line with the historic half year split). The Company continues to focus on maintaining low corporate overheads, thus providing a significant leverage to revenue growth.

Figure 1 below depicts the forecast revenue (low and high case), which were provided by XTE in its Company presentations (date 24 November 2017). We note that the revenues in these forecasts are based on the sales pipeline of over \$101m and a majority is made up of third-party resales to the Australian Defence Force. The manufacture and sales of ballistic plates from the new factory is **not** included in these forecasts.

Figure 1: Forecast Revenue

Forecast revenues (A\$m)



Source: XTEK Limited

We have used the above range of revenue forecasts as a basis for our valuations. We have derived a Bear case based on the low figures, a Bull case which is based on the high figures and a base case which is the midpoint of the low and high figures.

We note that timing and recognition of revenue could have a material impact on revenue reported in FY18, with a large portion of sales and deliveries occurring close to the financial year end. If sales were to be pushed into FY19, it would mean that FY18 financial results would be on the lower end of guidance (and may be viewed negatively by the market) but would increase the revenue range in FY19.

The changes in our three scenarios only arise from revenue assumptions for FY18, FY19 and FY20. All other assumptions are held constant in each scenario. Notable assumptions include: 7.5% revenue growth from FY21 to FY25 and 2.5% from FY26 onward (long-term growth rate); a flat growth profit margin of 30%, 9% compounded escalation in costs; 0% tax rate until FY21 (from tax losses); beta of 1.8 and a Weighted Average Cost of Capital (WACC) of 14.70%.

Base Case

Figure 2: Base Case - Financials

	2017A	2018F	2019F	2020F
Revenue	9.0	15.5	22.0	41.5
Cost of Sales	(5.5)	(10.9)	(15.4)	(29.1)
Gross Profit (GP)	3.5	4.7	6.6	12.5
<i>GP Margin</i>	38.8%	30.0%	30.0%	30.0%
EBITDA	0.2	0.3	1.7	6.8
<i>EBITDA Margin</i>	2.2%	2.0%	7.6%	16.4%
NPAT	0.1	0.2	1.2	6.4
<i>NPAT Margin</i>	0.7%	1.0%	5.6%	15.4%
EPS (cents)	0.2	0.4	3.1	16.0
P/E	210.2	104.8	14.0	2.7

Source: Patersons Securities Limited

Our base case assumes revenue of \$15.5m, \$22.0m and \$41.5m for FY18, FY19 and FY20 respectively. In our base case forecasts, both EBITDA and NPAT grow at an attractive rate over the next three fiscal periods, with a sharp uplift in FY20 highlighting the leverage from an increase in revenue versus sustained fixed costs. Our base case valuation of \$1.14/sh, which is c.160% above the current share price, highlights the valuation upside available from the current sales pipeline. We note significant further upside is evident, and not priced in, from further third-party sales and traction in sales from the in-house product suite.

Figure 3: Base Case - Valuation

DCF		
Beta		1.8x
WACC Post Tax		14.7%
DCF per share		\$1.14
Capitalisation of future earnings	2018F	2019F
EBITDA	0.3	1.7
EV/ EBITDA multiple	15.0x	15.0x
Enterprise value	4.6	25.1
Net cash/ (debt)	2.8	2.8
Equity value	1.8	22.3
Equity value per share	\$0.04	\$0.56

Source: Patersons Securities Limited

Bull Case

Figure 4: Bull Case - Financials

	2017A	2018F	2019F	2020F
Revenue	9.0	20.0	26.0	48.0
Cost of Sales	(5.5)	(14.0)	(18.2)	(33.6)
Gross Profit (GP)	3.5	6.0	7.8	14.4
<i>GP Margin</i>	38.8%	30.0%	30.0%	30.0%
EBITDA	0.2	1.7	2.9	8.7
<i>EBITDA Margin</i>	2.2%	8.3%	11.1%	18.2%
NPAT	0.1	1.5	2.4	8.3
<i>NPAT Margin</i>	0.7%	7.5%	9.4%	17.3%
EPS (cents)	0.2	4.0	6.1	20.9
P/E	218.2	10.9	7.1	2.1

Source: Patersons Securities Limited

Our bull case assumes revenue of \$20.0m, \$26.0m and \$48.0m for FY18, FY19 and FY20 respectively. In our bull case forecasts, both EBITDA and NPAT grow significantly over the next three fiscal periods, again with a sharp uplift in FY20 highlighting the leverage from an increase in revenue versus sustained fixed costs. Our bull case valuation of \$1.54/sh, which is c.250% above the current share price, highlights the valuation upside available from the upper end of the current sales pipeline. Again we note that there remains significant further upside, which is not priced in, from further third-party sales and traction in sales from the in-house product suite.

Figure 5: Bull Case -Valuation

DCF			
Beta			1.8x
WACC Post Tax			14.7%
DCF per share			\$1.54
Capitalisation of future earnings		2018F	2019F
EBITDA		1.7	2.9
EV/ EBITDA multiple		15.0x	15.0x
Enterprise value		24.9	43.1
Net cash/ (debt)		3.3	4.6
Equity value		21.6	38.5
Equity value per share		\$0.54	\$0.97

Source: Patersons Securities Limited

Bear Case

Figure 6: : Bear Case - Financials

	2017A	2018F	2019F	2020F
Revenue	9.0	11.0	18.0	35.0
Cost of Sales	(5.5)	(7.7)	(12.6)	(24.5)
Gross Profit (GP)	3.5	3.3	5.4	10.5
<i>GP Margin</i>	38.8%	30.0%	30.0%	30.0%
EBITDA	0.2	(1.0)	0.5	2.3
<i>EBITDA Margin</i>	2.2%	-9.5%	2.6%	6.7%
NPAT	0.1	(1.2)	0.0	1.9
<i>NPAT Margin</i>	0.7%	-10.8%	0.2%	5.5%
EPS (cents)	0.2	(3.2)	0.1	4.8
P/E	218.2	(18.4)	577.1	12.0

Source: Patersons Securities Limited

Our bear case assumes revenue of \$11.0m, \$18.0m and \$35.0m for FY18, FY19 and FY20 respectively. In our bear case forecasts, both EBITDA and NPAT are negative in FY18 and while there is growth in FY19 and FY20, the figures are not nearly as substantial as our base and bull case. Our bear case valuation of \$0.71/sh, which is c.70% above the current share price, highlights that there is valuation upside available from even the lowest end of the current sales pipeline. We note that even on our bear case, XTE appears to be undervalued, which may allude to the market having low confidence in the sales pipeline and/or capital robustness. We believe the low end of the sales pipeline should be the minimal level of revenue achievable given that SUAS contract should have a very high confidence level of execution attached.

Figure 7: Bear Case - Valuations

DCF			
Beta			1.8x
WACC Post Tax			14.7%
DCF per share			\$0.71
Capitalisation of future earnings		2018F	2019F
EBITDA		-1.0	0.5
EV/ EBITDA multiple		15.0x	15.0x
Enterprise value		-15.6	7.1
Net cash/ (debt)		2.4	1.1
Equity value		-18.0	6.0
Equity value per share		-\$0.45	\$0.15

Source: Patersons Securities Limited


BALANCE SHEET

The Company raised \$4.6m through a placement in June 2017 and a Share Purchase Plan in July 2017 at \$0.46/sh, which was slated for use in commercialising XTclave™, further development of XTAtlas™ and general working capital.

As at 31 March 2018, XTE had cash of \$3.6m and no debt. We expect the second half of FY18 to be stronger than the first, given the historical half year split seen in XTE's reporting.


Using our scenario forecasts, across all three scenarios XTE is slightly cashflow negative in FY18 and by FY20 is only cashflow negative in the bear case. We note that the cash balance remains steady in the base case and grows in the bull case, however there is a significant cash rake in our bear case. Thus, while XTE appears to not need a capital raising in the near-term, we believe the company could return to market to shore up its balance sheet in the next 12 to 18 months; particularly if revenue trends more toward the bear case scenario.

Figure 8: XTE Forecast Cash Position



Source: Patersons Securities Limited

Figure 9: XTE Forecast Cash Flow



Source: Patersons Securities Limited

Xtek Limited (XTE)	\$0.455			
Cash Flow (\$m)	2017A	2018F	2019F	2020F
Operating Cashflow	(1.4)	(0.6)	0.3	2.9
Capex	(0.1)	(1.1)	(0.3)	(0.3)
Disposals & Acquisitions	-	-	-	-
Other	-	-	-	-
Investing Cashflow	(0.1)	(1.1)	(0.3)	(0.3)
Equity Raised	3.8	1.7	-	-
Increase (Repay) Debt	-	-	-	-
Distributions Paid	-	-	-	-
Other	-	-	-	-
Financing Cashflow	3.8	1.7	-	-
Change in Cash Held	2.3	0.0	0.0	2.6
Closing Cash Balance	2.8	2.8	2.8	5.4

	Year End June 30			
Profit & Loss (\$m)	2017A	2018F	2019F	2020F
Sales Revenue	9.0	15.5	22.0	41.5
Cost of Sales	(5.5)	(10.9)	(15.4)	(29.1)
Gross Profit	3.5	4.7	6.6	12.5
Other Income (expense)	0.6	-	-	-
Employee Benefits	(2.3)	(2.5)	(2.8)	(3.2)
Operational Expenditure	(1.6)	(1.8)	(2.1)	(2.4)
Reported EBITDA	0.2	0.3	1.7	6.8
Depn & Amort	(0.1)	(0.1)	(0.4)	(0.4)
EBIT	0.1	0.2	1.3	6.4
Net Interest	(0.1)	(0.1)	(0.1)	(0.1)
PBT	0.1	0.2	1.2	6.4
Tax expense	-	-	-	-
Abnormals	-	-	-	-
NPAT (Reported)	0.1	0.2	1.2	6.4



Balance Sheet (\$m)	2017A	2018F	2019F	2020F
Cash	2.8	2.8	2.8	5.4
Receivables	2.6	3.1	4.4	8.3
Inventories	0.9	2.0	2.9	5.4
Intangibles	0.1	0.1	0.1	0.1
Property, Plant & Equipment	0.3	1.4	1.3	1.3
Other	0.7	0.7	0.7	0.7
Assets	7.3	10.0	12.1	21.1
Payables	1.2	2.1	2.9	5.5
Borrowings	-	-	-	-
Provisions	0.2	0.2	0.2	0.2
Other liabilities	0.3	0.3	0.3	0.3
Liabilities	1.7	2.6	3.4	6.0
Shareholders Funds	5.6	7.5	8.7	15.1

Valuation	
DCF	
Beta	1.8x
WACC Post Tax	14.7%
DCF per share	\$1.14

EPS & DPS	2017A	2018F	2019F	2020F
EPS (Cents Reported)	0.2	0.4	3.1	16.0
EPS growth (%)	(102.9)	108.1	649.9	413.7
DPS (cents)	-	-	-	-
Payout Ratio (%)	-	-	-	-
Dividend Yield (%)	-	-	-	-

Capitalisation of future earnings	
EBITDA	0.3
EV/ EBITDA multiple	15.0x
Enterprise value	5
Net cash/ (debt)	2.8

Ratios	2017A	2018F	2019F	2020F
Profitability				
NPAT Growth (%)	(103.9)	156.0	691.0	413.7
Sales Growth (%)	169.1	71.8	41.9	88.6
Gross Margin (%)	38.8	30.0	30.0	30.0
Reported EBITDA Margin (%)	2.2	2.0	7.6	16.4
ROC (%)	4.3	4.6	22.1	66.3
ROE (%)	1.1	2.1	14.2	42.2
Tax Rate (%)	-	-	-	-

Equity value	
Equity value per share	\$0.56


Valuation	2017A	2018F	2019F	2020F
Price/Earnings (x)	228.2	109.6	14.6	2.8
EV/EBITDA (x)	69.0	49.7	9.1	1.9
Price/NTA (x)	2.9	2.5	2.1	1.2

Directors & substantial shareholders	
Name	Position
Uwe Boettcher	Chairman
Philippe Odouard	Managing Director
Robert Quodling	Executive Director
Ivan Slavich	Non Executive Director
Chris Fullerton	Non Executive Director

Balance Sheet	2017A	2018F	2019F	2020F
Net Debt/Equity (%)	(50.3)	(37.9)	(32.5)	(35.7)
Net Debt/Assets (%)	(38.5)	(28.2)	(23.3)	(25.5)
Interest Cover (x)	2.1	3.7	22.4	110.8
NTA (\$/share)	0.2	0.2	0.2	0.4
Shares (m)	35.7	39.8	39.8	39.8

Shareholder	No. shares (m)	%
UBD Pty Limited	3.99	10.0
Wendy Wing Lin Lo	2.53	6.3
Fairlane Management	2.10	5.3
Top 20 shareholders	17.66	44.3

Recommendation History



Date	Type	Target Price	Share Price	Recommendation	Return
08 Feb 18	Research Note	1.15	0.67	SB	
	Current Share Price		0.46		-32.1%

Stock recommendations: Investment ratings are a function of Patersons expectation of total return (forecast price appreciation plus dividend yield) within the next 12 months. The investment ratings are Buy (expected total return of 10% or more), Hold (-10% to +10% total return) and Sell (> 10% negative total return). In addition we have a Speculative Buy rating covering higher risk stocks that may not be of investment grade due to low market capitalisation, high debt levels, or significant risks in the business model. Investment ratings are determined at the time of initiation of coverage, or a change in target price. At other times the expected total return may fall outside of these ranges because of price movements and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. This Document is not to be passed on to any third party without our prior written consent.



1300 582 256

patersons@psl.com.au

www.psl.com.au

Patersons Securities Limited Disclosure of Interest

Patersons Securities and its respective officers and associates may have an interest in the securities or derivatives of any entities referred to in this material

Patersons Securities does, and seeks to do, business with companies that are the subjects of its research reports.

Patersons Securities Corporate Relationship Disclosure

88E	Patersons Securities have acted for 88 Energy Ltd (88E) within the past year and have received fees for these services.
AGR	Patersons Securities have acted for Agua Resources Ltd (AGR) within the past year and have received fees for these services.
AGY	Patersons Securities have acted for Argosy Minerals Ltd (AGY) within the past year and have received fees for these services.
AJL	Patersons Securities have acted for AJ Lucas Group Ltd (AJL) within the past year and have received fees for these services.
AKM	Patersons Securities have acted for Aspire Mining Ltd (AKM) within the past year and have received fees for these services.
AO1	Patersons Securities have acted for AssetOwl Limited (AO1) within the past year and have received fees for these services.
AXL	Patersons Securities have acted for Axesstoday Ltd (AXL) within the past year and have received fees for these services.
BOE	Patersons Securities have acted for Boss Resources Ltd (BOE) within the past year and have received fees for these services.
BRB	Patersons Securities have acted for Breaker Resources NL (BRB) within the past year and have received fees for these services.
BUX	Patersons Securities have acted for Buxton Resources Ltd (BUX) within the past year and have received fees for these services.
CSS	Patersons Securities have acted for Clean Seas Seafood Ltd (CSS) within the past year and have received fees for these services.
CTL	Patersons Securities have acted for Centennial Mining Ltd (CTL) within the past year and have received fees for these services.
DRG	Patersons Securities have acted for Draig Resources Ltd (DRG) within the past year and have received fees for these services.
DRO	Patersons Securities have acted for DroneShield Ltd (DRO) within the past year and have received fees for these services.
GLL	Patersons Securities have acted for Galilee Energy Ltd (GLL) within the past year and have received fees for these services.
IBG	Patersons Securities have acted for Ironbark Zinc Ltd (IBG) within the past year and have received fees for these services.
IPT	Patersons Securities have acted for Impact Minerals Ltd (IPT) within the past year and have received fees for these services.
NUS	Patersons Securities have acted for Nusantara Resources (NUS) within the past year and have received fees for these services.
PEX	Patersons Securities have acted for Peel Mining Ltd (PEX) within the past year and have received fees for these services.
PGO	Patersons Securities have acted for Primary Gold Ltd (PGO) within the past year and have received fees for these services.
RCL	Patersons Securities have acted for Readcloud Limited (RCL) within the past year and have received fees for these services.
SYA	Patersons Securities have acted for Sayona Mining Ltd (SYA) within the past year and have received fees for these services.
UUV	Patersons Securities have acted for UUV Aquabotix Ltd (UUV) within the past year and have received fees for these services.
VMY	Patersons Securities have acted for Vimy Resources Ltd (VMY) within the past year and have received fees for these services.
WKT	Patersons Securities have acted for Walkabout Resources Ltd (WKT) within the past year and have received fees for these services.
XAM	Patersons Securities have received corporate advisory fees from Xanadu Mines Ltd (XAM) within the past year.
XTE	Patersons Securities have acted for Xtek Ltd (XTE) within the past year and have received fees for these services.

Research

Cathy Moises - Head of Research	Phone: (+61 3) 9242 4030	Email: cmoises@psl.com.au
Hira Sakrani - Associate Analyst	Phone: (+61 3) 9242 4052	Email: hsakrani@psl.com.au
James Farr - Research Assistant	Phone: (+61 8) 9263 1215	Email: jfarr@psl.com.au
Daniel Veasey - Research Assistant	Phone: (+61 8) 9225 2818	Email: dveasey@psl.com.au

Strategy & Economics

Tony Farnham - Economic Strategist / Analyst	Phone: (+61 2) 9258 8973	Email: tfarnham@psl.com.au
Greg Galton - Private Wealth, Analyst	Phone: (+61 8) 9263 1612	Email: ggalton@psl.com.au

Commodities

Cam Hardie - Analyst	Phone: (+61 3) 9242 4153	Email: chardie@psl.com.au
Simon Tonkin - Senior Analyst	Phone: (+61 8) 9225 2816	Email: stonkin@psl.com.au
Xavier Braud - Analyst	Phone: (+61 8) 9225 2813	Email: xbraud@psl.com.au

Industrials

Martyn Jacobs - Analyst	Phone: (+61 3) 9242 4153	Email: mjacobs@psl.com.au
Jon Scholtz - Analyst	Phone: (+61 8) 9225 2836	Email: jscholtz@psl.com.au

Institutional Dealing

Dan Bahen	Phone: (+61 8) 9263 1274	Email: dbahen@psl.com.au
Michael Brindal	Phone: (+61 8) 9263 1186	Email: mbrindal@psl.com.au
Artie Damaa	Phone: (+61 2) 8238 6215	Email: adamaa@psl.com.au
Paul Doherty	Phone: (+61 3) 8803 0108	Email: pdoherty@psl.com.au
Chris Kelly	Phone: (+61 3) 9242 4078	Email: ckelly@psl.com.au
Jeremy Nugara	Phone: (+61 3) 8803 0166	Email: jnugara@psl.com.au
Phil Schofield	Phone: (+61 2) 8238 6223	Email: pschofield@psl.com.au
Sandy Wylie	Phone: (+61 8) 9263 1232	Email: swylie@psl.com.au

Important Notice: Copyright 2017. The Contents contained in this report are owned by Patersons Securities Limited ('Patersons') and are protected by the Copyright Act 1968 and the copyright laws of other countries. The material contained in this report may not be copied, reproduced, republished, posted, transmitted or distributed in any way without prior written permission from Patersons. Modification of the materials for any other purpose is a violation of the copyrights and other proprietary rights of Patersons.

Disclaimer: Patersons believes that the information or advice (including any financial product advice) contained in this report has been obtained from sources that are accurate at the time of issue, but it has not independently checked or verified that information and as such does not warrant its accuracy or reliability. Except to the extent that liability cannot be excluded, Patersons accepts no liability or responsibility for any indirect loss or damage caused by any error in or omission from this report. You should make and rely on your own independent inquiries. If not specifically disclosed otherwise, investors should assume that Patersons is seeking or will seek corporate finance business from the companies disclosed in this report.

Warning: This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate to your particular investment objectives, financial situation or particular needs. Prior to making any investment decision, you should assess, or seek advice from your adviser, on whether any relevant part of this report is appropriate to your financial circumstances and investment objectives.

Disclosure: Patersons, its directors and/or employees may earn brokerage, fees, commissions and other benefits as a result of a transaction arising from any advice mentioned in this report. Patersons as principal, its directors and/or employees and their associates may hold securities in the companies the subject of this report, as at the date of publication. These interests do not influence Patersons in giving the advice contained in this report. Details of any interests may be obtained from your adviser. Patersons as principal, its directors and/or employees and their associates may trade in these securities in a manner which may be contrary to recommendations given by an authorised representative of Patersons to clients. They may sell shares the subject of a general 'Buy' recommendation, or buy shares the subject of a general 'Sell' recommendation.

Stock recommendations: Investment ratings are a function of Patersons expectation of total return (forecast price appreciation plus dividend yield) within the next 12 months. The investment ratings are Buy (expected total return of 10% or more), Hold (-10% to +10% total return) and Sell (> 10% negative total return). In addition we have a Speculative Buy rating covering higher risk stocks that may not be of investment grade due to low market capitalisation, high debt levels, or significant risks in the business model. Investment ratings are determined at the time of initiation of coverage, or a change in target price. At other times the expected total return may fall outside these ranges because of price movements and/or volatility. Such interim deviations from specified ratings will be permitted but will become subject to review by Research Management. This Document is not to be passed to any third party without prior written consent.